Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849728 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
A Phase 3 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Inventiva Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT04849728 is a Phase 3 study of NASH - Nonalcoholic Steatohepatitis that is actively recruiting participants, run by Inventiva Pharma. The registered enrollment target is 1,000 participants, above the 232-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (331% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04849728, a Phase 3 study of NASH - Nonalcoholic Steatohepatitis, is actively recruiting participants, sponsored by Inventiva Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IVA337
Study Locations (20)
Arizona
- The Institute For Liver Health - Chandler - Chandler
- Arizona Liver Health - Peoria - Peoria
- Saint Joseph's Hospital and Medical Center - Phoenix
- Arizona Digestive Health - Sun City - Tucson
- Adobe Gastroenterology - Tucson
- Arizona Liver Health - Tucson
- Del Sol Research Management - Tucson East - Tucson
California
- Office of Franco Felizarta, MD - Bakersfield
- Fomatmedicalresearch - Camarillo
- Precision Research Institute - Chula Vista
- GW Research - Chula Vista
- Velocity Clinical Research, Chula Vista - Chula Vista
Alabama
- Pinnacle Research Group - Anniston
- Objective Health - Birmingham Gastroenterology Associates - Birmingham
- Digestive Health Specialist of the Southeast - Dothan
- North Alabama GI Research Center llc - Madison
Arkansas
- ARcare Center for Clinical Research - Conway - Conway
- ARcare Center for Clinical Research - Little Rock
- Arkansas Diagnostic Center - Little Rock
- Arkansas Gastroenterology - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04849728
The ClinicalTrials.gov registry entry for NCT04849728 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (331% higher). The listed sponsor is Inventiva Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04849728 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04849728 about?
NCT04849728 is a clinical study titled "A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )". This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
What is the current status of trial NCT04849728?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2021-08-19. Estimated completion is 2026-09-30.
What conditions does trial NCT04849728 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04849728?
The interventions under investigation include: Placebo (DRUG), IVA337 (DRUG).
Who is sponsoring clinical trial NCT04849728?
This trial is sponsored by Inventiva Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04849728 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.